Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Apigenin in preparation of drugs for prevention and treatment on chronic obstructive pulmonary diseases

A technology for chronic obstructive pulmonary disease, used in drug combinations, respiratory diseases, pharmaceutical formulations, etc., can solve problems such as slow progress in drug treatment research, different pathogenesis, and difficulty in obtaining satisfactory curative effects.

Inactive Publication Date: 2018-04-03
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no drug that can curb the progressive development of COPD, and the research progress of its drug treatment is quite slow. At present, the drug for treating asthma is often used in clinical practice to treat COPD. Because the pathogenesis of COPD is different from that of asthma, it is difficult to obtain satisfactory curative effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Apigenin in preparation of drugs for prevention and treatment on chronic obstructive pulmonary diseases
  • Use of Apigenin in preparation of drugs for prevention and treatment on chronic obstructive pulmonary diseases
  • Use of Apigenin in preparation of drugs for prevention and treatment on chronic obstructive pulmonary diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: the preparation of compound Apigenin tablet involved in the present invention:

[0016] Take 5 grams of the compound Apigenin, add 195 grams of dextrin, mix well, and make 1000 tablets with a conventional tablet machine.

Embodiment 2

[0017] Embodiment 2: the preparation of compound Apigenin capsules involved in the present invention:

[0018] Take 5 grams of the compound Apigenin, add 195 grams of starch, mix well, and make 1000 capsules.

[0019] The following pharmacodynamic experiments will further illustrate its drug activity.

[0020] Methods: SPF grade female BALB / c mice, 18-20g, were randomly divided into normal control group, model control group, positive control group (terbutaline, 10mg / kg, intragastric administration), drug treatment group (Apigenin 5, 10, 20mg / kg, intragastric administration), 10 rats in each group. The mice were placed in a 4L container and smoked every day (Jinjian brand cigarettes, tar content less than 16mg), five times a week, for four consecutive weeks, administered by intragastric administration 1 hour before the daily smoke. One hour after fumigation, anesthetize with sodium phenobarbital, perfuse the lungs with 0.6 mL of pre-cooled PBS buffer (pH 7.0), rinse 3 times, ...

experiment example 1

[0021] Experimental Example 1: Inhibitory effect of Apigenin on the production of inflammatory mediators in bronchoalveolar lavage fluid (BALF) of COPD mice (1) Inhibitory effect of Apigenin on the production of TNFα in BALF of COPD mice

[0022] The proinflammatory cytokine TNFα is an initiating factor in the pathogenesis of COPD. The level of TNFα in COPD patients is higher than that of normal people, and the cultured bronchial epithelial cells can secrete TNFα in contact with cigarette smoke. TNFα can promote neutrophil degranulation, induce mucosal cell proliferation and hypersecretion, increase the production of IL-8 in epithelial cells, increase the production of matrix metalloproteinases in macrophages, and promote airway hyperresponsiveness. The purpose of this experiment is to investigate the effect of Apigenin on the production of TNFα in the BALF of COPD mice. The results are shown in Table 1.

[0023] Table 1 The effect of Apigenin on the production of TNFα in the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new application of Apigenin in the preparation of medicaments for preventing and treating chronic obstructive pulmonary disease. The use of Apigenin involved in the present invention in the preparation of anti-chronic obstructive pulmonary disease medicines belongs to the first disclosure. Since the skeleton type belongs to a brand-new skeleton type, and its inhibitory activity against chronic obstructive pulmonary disease is so strong that it is unexpected, there is no such thing as a drug given by other compounds. It has outstanding substantive features, and it is obviously a significant progress for the anti-chronic obstructive pulmonary disease.

Description

technical field [0001] The invention relates to a new application of compound Apigenin, in particular to the application of Apigenin in the preparation of medicines for treating chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) is a common chronic disease worldwide, currently ranking fourth in the global cause of death, according to the World Health Organization forecast, by 2020, COPD will be in the global disease Ranked fifth and third among causes of death. [0003] COPD is a disease characterized by not fully reversible airflow limitation associated with an abnormal inflammatory response of the lungs to noxious gases or noxious particles, with chronic inflammation throughout the airways, lung parenchyma, and pulmonary vessels. The cells involved in COPD include inflammatory cells such as neutrophils, T lymphocytes, and macrophages. When the cells are activated, they re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K9/48A61K9/20A61P11/00
CPCA61K31/352A61K9/2059A61K9/4866
Inventor 田丽华
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com